|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 310.00 USD | +1.43% |
|
+2.03% | +2.04% |
| 15/04 | Molecular Partners AG Announces Board and Committee Appointments | CI |
| 15/04 | BeOne Medicines AG says 2025 net profit at 1.5 billion yuan | RE |
Business description: BeOne Medicines AG
Number of employees: 12,000
Sales by Activity: BeOne Medicines AG
| Fiscal Period: December | 2021 (USD) | 2022 (USD) | 2023 (USD) | 2024 (USD) | 2025 (USD) |
|---|---|---|---|---|---|
Pharmaceutical Products | 1.18B | 1.42B | 2.46B | 3.81B | 5.34B |
Geographical breakdown of sales: BeOne Medicines AG
| Fiscal Period: December | 2021 (USD) | 2022 (USD) | 2023 (USD) | 2024 (USD) | 2025 (USD) |
|---|---|---|---|---|---|
United States (U.S) | 495M | 503M | 1.13B | 1.96B | 2.88B |
China | 517M | 840M | 1.1B | 1.41B | 1.68B |
Europe | - | - | 202M | 363M | 611M |
Rest of World | 164M | 73.26M | 26.6M | 78.81M | 172M |
Executive Committee: BeOne Medicines AG
| Manager | Title | Age | Since |
|---|---|---|---|
John Oyler
CEO | Chief Executive Officer | 57 | 28/10/2010 |
Aaron Rosenberg
DFI | Director of Finance/CFO | 50 | 22/07/2024 |
Xiao Bin Wu
PSD | President | 64 | 01/04/2018 |
Lai Wang
PSD | President | 49 | 17/12/2025 |
Yang Ji
CMP | Compliance Officer | - | 01/09/2017 |
Composition of the Board of Directors: BeOne Medicines AG
| Director | Title | Age | Since |
|---|---|---|---|
John Oyler
CHM | Chairman | 57 | 27/01/2016 |
Michael Goller
BRD | Director/Board Member | 51 | 01/04/2015 |
Ranjeev Krishana
BRD | Director/Board Member | 52 | 01/10/2014 |
Qing Qing Yi
BRD | Director/Board Member | 54 | 01/10/2014 |
Xiao Dong Wang
CHM | Chairman | 62 | 28/10/2010 |
Anthony Hooper
BRD | Director/Board Member | 71 | 01/01/2020 |
Corazon Sanders
BRD | Director/Board Member | 69 | 24/08/2020 |
Alessandro Riva
BRD | Director/Board Member | 65 | 01/02/2022 |
Margaret Dugan
BRD | Director/Board Member | 69 | 01/02/2022 |
| Director/Board Member | 70 | 22/01/2024 |
Holdings: BeOne Medicines AG
| Name | Equities | % | Valuation |
|---|---|---|---|
| 1,215,306 | 1.35% | 966 168 $ |
Company details: BeOne Medicines AG
Other Biotechnology & Medical Research
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +1.43% | +2.03% | +27.70% | +17.42% | 33.9B | |
| +2.32% | +3.28% | +1.03% | -9.01% | 45.84B | |
| +1.91% | +2.73% | +16.14% | -12.51% | 28.87B | |
| +2.00% | +1.69% | +28.53% | +20.92% | 27.52B | |
| +7.86% | +52.67% | +303.10% | +564.00% | 27.01B | |
| -6.61% | +8.08% | +3,405.65% | +3,986.59% | 15.94B | |
| +0.52% | +13.32% | +60.67% | +207.80% | 15.36B | |
| +3.74% | +2.26% | +70.34% | +170.64% | 14.31B | |
| +5.52% | +5.29% | +37.68% | +10.42% | 13.37B | |
| +2.41% | +3.88% | +167.64% | +107.46% | 12.38B | |
| Average | +2.11% | +5.31% | +411.85% | +506.37% | 23.45B | |
| Weighted average by Cap. | +2.29% | +5.57% | +295.25% | +367.96% |
Sector
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- ONC Stock
- Company BeOne Medicines AG
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition